Clinical  	Clinical  	 JJ	B-NP
trial  	trial  	 NN	I-NP
experience  	experience  	 NN	I-NP
with  	with  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
renal  	renal  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 VBZ	O
Clinical  	Clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
have  	have  	 VBP	O
validated  	validated  	 VBG	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
mammalian  	mammalian  	 JJ	B-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin  	rapamycin  	 NNS	I-NP
( 	( 	 -LRB-	O
mTOR 	mTOR 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
a  	a  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
target  	target  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
renal  	renal  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
RCC 	RCC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
TORC1  	TORC1  	 JJ	B-NP
complex  	complex  	 JJ	I-NP
controls  	controls  	 NNS	I-NP
translation  	translation  	 NN	I-NP
of  	of  	 IN	I-NP
key  	key  	 JJ	I-NP
proteins  	proteins  	 NNS	I-NP
involved  	involved  	 VBN	O
in  	in  	 IN	O
cell  	cell  	 NN	O
proliferation  	proliferation  	 NN	O
and  	and  	 CC	O
regulates  	regulates  	 VBZ	O
the  	the  	 DT	O
expression  	expression  	 NN	O
and  	and  	 CC	O
stability  	stability  	 NN	O
of  	of  	 IN	O
hypoxia-inducible  	hypoxia-inducible  	 JJ	B-NP
factor  	factor  	 NN	I-NP
( 	( 	 -LRB-	O
HIF 	HIF 	 NNP	B-NP
) 	) 	 -RRB-	O
-1alpha 	-1alpha 	 NNP	O
.  	.  	 .	O
Temsirolimus 	Temsirolimus 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
first  	first  	 JJ	O
mTOR  	mTOR  	 JJ	B-NP
inhibitor  	inhibitor  	 NNS	I-NP
approved  	approved  	 VBN	O
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
RCC 	RCC 	 NNP	B-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
demonstrated  	demonstrated  	 VBN	O
significantly  	significantly  	 RB	O
longer  	longer  	 RBR	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
( 	( 	 -LRB-	O
hazard  	hazard  	 NN	B-NP
ratio  	ratio  	 NN	I-NP
for  	for  	 IN	O
death 	death 	 NN	O
,  	,  	 ,	O
0.73 	0.73 	 CD	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval 	interval 	 NN	I-NP
,  	,  	 ,	O
0.58-0.92 	0.58-0.92 	 NNP	O
,  	,  	 ,	O
P  	P  	 NN	O
=  	=  	 SYM	O
.008 	.008 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
progression-free  	progression-free  	 JJ	B-NP
survival  	survival  	 NN	I-NP
( 	( 	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
interferon  	interferon  	 JJ	B-NP
alfa  	alfa  	 NNS	O
( 	( 	 -LRB-	O
IFN 	IFN 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
poor  	poor  	 JJ	O
prognostic  	prognostic  	 JJ	B-NP
features 	features 	 NNS	I-NP
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
durations  	durations  	 NNS	I-NP
were  	were  	 VBD	O
3.8  	3.8  	 CD	O
and  	and  	 CC	O
1.9  	1.9  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
,  	,  	 ,	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
or  	or  	 CC	O
IFN 	IFN 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
median  	median  	 JJ	B-NP
overall  	overall  	 JJ	O
survivals  	survivals  	 NN	O
were  	were  	 VBD	O
10.9  	10.9  	 CD	O
and  	and  	 CC	O
7.3  	7.3  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Exploratory  	Exploratory  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
indicate  	indicate  	 VBP	O
that  	that  	 IN	O
temsirolimus  	temsirolimus  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
those  	those  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
metastatic  	metastatic  	 JJ	B-NP
RCC  	RCC  	 NNP	I-NP
and  	and  	 CC	O
multiple  	multiple  	 JJ	O
adverse  	adverse  	 JJ	O
prognostic  	prognostic  	 JJ	B-NP
factors  	factors  	 NNS	I-NP
regardless  	regardless  	 RB	O
of  	of  	 IN	O
tumor  	tumor  	 NN	B-NP
histology  	histology  	 NNS	I-NP
or  	or  	 CC	O
nephrectomy  	nephrectomy  	 JJ	B-NP
status 	status 	 NN	I-NP
.  	.  	 .	O
Most  	Most  	 RBS	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
that  	that  	 WDT	O
occur  	occur  	 VBP	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
temsirolimus  	temsirolimus  	 NNS	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
managed  	managed  	 VBN	O
medically  	medically  	 NNS	O
( 	( 	 -LRB-	O
eg 	eg 	 UH	B-NP
,  	,  	 ,	O
hyperglycemia 	hyperglycemia 	 NN	B-NP
,  	,  	 ,	O
hyperlipidemia 	hyperlipidemia 	 CD	B-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
addressed  	addressed  	 VBN	O
by  	by  	 IN	O
supportive  	supportive  	 JJ	B-NP
measures  	measures  	 NNS	I-NP
( 	( 	 -LRB-	O
eg 	eg 	 UH	B-NP
,  	,  	 ,	O
stomatitis 	stomatitis 	 NN	B-NP
,  	,  	 ,	O
rash 	rash 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Although  	Although  	 IN	O
development  	development  	 NN	O
of  	of  	 IN	O
symptomatic  	symptomatic  	 JJ	B-NP
pneumonitis  	pneumonitis  	 NN	I-NP
is  	is  	 VBZ	O
rare 	rare 	 JJ	O
,  	,  	 ,	O
monitoring  	monitoring  	 NN	O
is  	is  	 VBZ	O
recommended 	recommended 	 VBN	O
.  	.  	 .	O
Temsirolimus  	Temsirolimus  	 NNP	B-NP
is  	is  	 VBZ	O
now  	now  	 RB	O
considered  	considered  	 VBN	O
an  	an  	 DT	O
important  	important  	 JJ	O
first-line  	first-line  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
option  	option  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
RCC  	RCC  	 NNP	B-NP
and  	and  	 CC	O
multiple  	multiple  	 JJ	O
factors  	factors  	 NNS	O
predictive  	predictive  	 VBN	O
of  	of  	 IN	O
short  	short  	 JJ	O
survival 	survival 	 NN	O
.  	.  	 .	O
Current  	Current  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
are  	are  	 VBP	O
investigating  	investigating  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
in  	in  	 IN	O
sequence  	sequence  	 NN	O
or  	or  	 CC	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
other  	other  	 JJ	O
targeted  	targeted  	 JJ	O
agents  	agents  	 NNS	O
to  	to  	 TO	O
further  	further  	 RB	O
improve  	improve  	 VB	O
outcomes 	outcomes 	 NNS	O
.  	.  	 .	O
